Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SMD-3040 |
| Synonyms | |
| Therapy Description |
SMD-3040 is a proteolysis-targeted chimera (PROTAC) that binds to SMARCA2 and targets it for degradation, potentially inhibiting cell proliferation and growth of SMARCA4-deficient tumors (PMID: 37523716). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SMD-3040 | SMD3040|SMD 3040 | SMD-3040 is a proteolysis-targeted chimera (PROTAC) that binds to SMARCA2 and targets it for degradation, potentially inhibiting cell proliferation and growth of SMARCA4-deficient tumors (PMID: 37523716). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| SMARCA4 del | lung non-small cell carcinoma | sensitive | SMD-3040 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SMD-3040 inhibited proliferation of a non-small cell lung cancer cell line with SMARCA4 deletion in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 37523716). | 37523716 |
| SMARCA4 del | melanoma | sensitive | SMD-3040 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SMD-3040 inhibited proliferation of a melanoma cell line with SMARCA4 deletion in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 37523716). | 37523716 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|